• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Triazole Derivatives
    5 Drugs classified under this drug class


    All the Drug Class Drugs

    Cresemba 100 mg Capsules
    Pfizer
    RX
    partial basket chart
    Cresemba 100 mg Capsules

    Antimycotic, Triazole Derivatives. Isavuconazole 100 mg.
    CAPS.: 14. Loading dose is 2 caps (200mg)×3/d every 8 hrs. for the first 48 hrs. (6 admin. in total).
    Mainten. dose: 2 caps. (200mg)×1/d, start. 12-24 hrs. after the last load. dose. Durat. of ther. should be determin. by the clinic. response.
    For long-term tmt. beyond 6 mnths., the benefit-risk balance should be careful. consid.
    Tmt. of invas. aspergillosis; mucormycosis in pt. for whom amphotericin B is inapprop.  Consider. should be given to offic. guidance on the approp. use of antifung. agents.
    C/I: Hypersens. Co-admin. with ketoconazole. Co-admin. with high-dose ritonavir (>200 mg every 12 hrs). Co-admin. with strong CYP3A4/5 induc. such as rifampicin, rifabutin, carbamazepine, long-act. barbiturates (e.g. phenobarbital), phenytoin and St. John’s wort or with moder. CYP3A4/5 induc. such as efavirenz, nafcillin & etravirine. Pts. with famil. short QT syndr.

    Cresemba 200 mg IV
    Pfizer
    RX
    partial basket chart
    Cresemba 200 mg IV

    Antimycotic, Triazole Derivatives. Isavuconazole 200 mg.
    VIAL (pwdr. for concentrat. for sol. for infus.): 1×10ml. Load. dose: The recomm. load. dose is 1 vial after reconstit. & dilute. (equiv. to 200 mg of isavuconazole) every 8 hrs. for the first 48 hrs. (6 admin. in total).
    Mainten. dose: The recom. mainten. dose is one vial after reconstit. and dilute. (equiv. to 200 mg of isavuconazole) once dly., starting 12- 24 hrs. after the last load. dose.
    Durat. of therapy should be determ. by the clinical response.
    For long-term tmt. beyond 6 mnths., the benefit-risk balance should be carefully considered.
    Switch to oral isavuconazole: This drug  is also available as hard caps. contain. 100 mg isavuconazole, equiv. to 186 mg isavuconazonium sulfate. See lit.
    Indic. in adult. for the tmt. of: Invasive aspergillosis, mucormycosis in pts. for whom amphotericin B is inappropr.
    Consideration should be given to official guidance on the appropr. use of antifung. agents.
    C/I: Hypersens. Co-admin. with ketoconazole. Co-admin. with high-dose ritonavir (>200 mg every 12 hrs.).
    Co-admin. with strong CYP3A4/5 induc. such as rifampicin, rifabutin, carbamazepine, long-act. barbiturates (e.g. phenobarbital), phenytoin and St. John’s wort or with moder. CYP3A4/5 induc. (e.g. efavirenz, nafcillin, etravirine). Pts. with familial short QT syndr.

    Noxafil Tablets
    MSD
    RX
    partial basket chart
    Noxafil Tablets

    Triazole Derivatives. Posaconazole 100 mg.
    GASTRO-RESIS. TABS.:24. Refract. invas. fung. infect. (IFI)/pts. with IFI intoler. to 1st line ther.: Load. dose of 300 mg (three 100 mg tabs.) ×2/d on the 1st day, then 300 mg (three 100 mg tabs.) ×1/d thereafter.
    Each dose may be taken without regard to food intake. Duration of ther. should be based on the severity of the underl. dis., recovery from immunosuppress., and clinic. response.
    Prophylax. of invas. fung. infec.: Load. dose of 300 mg (three 100 mg tabs.) ×2/d on the 1st day, then 300 mg (three 100 mg tabs.) ×1/d thereafter.
    Each dose may be taken without regard to food intake. Duration of ther. is based on recovery from neutrop. or immunosuppress. For pts. with acute myelogenous leukem. or myelodysplas. syndr., prophylax. with posaconazole should start several days before the anticip. onset of neutropen. and cont. for 7 d. after the neutrophil count rises above 500 cells per mm3. See lit.
    Tmt. of the follow. fung. infec. in adult.
    Invas. aspergillos. in pts. with dis. that is refract. to amphotericin B or itraconazole or in pts. who are intoler. of these med. products;
    Fusariosis in pts. with dis. that is refract. to amphotericin B or in pts. who are intoler. of amphotericin B;
    Chromoblastomycosis & mycetoma in pts. with dis. that is refract. to itraconazole or in pts. who are intoler. of itraconazole;
    Coccidioidomycosis in pts. with dis. that is refract. to amphotericin B, itraconazole or fluconazole or in pts.who are intoler. of these med. products.
    Zygomycosis in pts. intoler. of or with dis. that is refract. to alternat. ther.
    Refractoriness is defined as progres. of infec. or failure to improve after a min. of 7 d. of prior therap. doses of effective antifung. ther.
    Prophylax. of invas. fung. infect. in the follow.: Pts. receiv. remiss. –induct. chemother. for acute myelogenous leukemia (AML) or myelodysplastic syndr. (MDS) expected to result in prolong. neutropen. and who are at high risk of develop. invas. fung. infect.;
    Hematopoiet. stem cell transplant (HSCT) recipients who are underg. high-dose immunosuppress. ther. for graft versus host dis. and who are at high risk of develop. invas. fung. infect.
    C/I: Hypersens. Co-admin. with ergot alkaloid. Co-admin. with the CYP3A4 substrates terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine since this may result in incr. plasma conc. of these med. products, leading to QTc prolong. and rare occurrences of torsades de pointes.
    Co-admin. with the HMG-CoA reductase inhib. simvastatin, lovastatin and atorvastatin.

    CLOSE